Arvinas, Inc.
- Open
- 9.68
- Day high
- 9.69
- Day low
- 9.43
- Prev close
- 9.59
- Volume
- 40K
- Mkt cap
- $627M
- P/E (TTM)
- 50.5
- EPS (TTM)
- $0.19
- P/B
- 1.1
- P/S
- 2.0
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$66K over the last 3 months (0 open-market buys, 2 sales)
- 🏛Institutions accumulating (13F)
Arvinas, Inc. (ARVN) is a Healthcare company listed on NASDAQ. The stock is up 19% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 2 sales (SEC Form 4). Drillr has 1 published research article covering ARVN.
Arvinas, Inc. (ARVN) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 6 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ARVN earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 4, 2026 | $-0.37 | $2.58 | +789.6% | $250M | +311.3% |
| May 12, 2026 | $-0.95 | $-0.90 | +5.3% | $16M | -6.1% |
| Feb 24, 2026 | $-0.55 | $-1.10 | -100.0% | $10M | -61.3% |
| Nov 5, 2025 | $-0.75 | $-0.48 | +36.0% | $42M | +12.4% |
| Aug 6, 2025 | $-0.87 | $-0.84 | +3.4% | $22M | -10.4% |
| May 1, 2025 | $-0.86 | $1.14 | +232.6% | $189M | +346.3% |
| Feb 27, 2024 | $-1.33 | $-2.53 | -90.2% | $43M | -12.6% |
| May 5, 2023 | $-1.46 | $-1.54 | -5.5% | $33M | +17.3% |
| Feb 23, 2023 | $-1.04 | $-1.56 | -50.0% | $38M | +6.4% |
| Aug 4, 2022 | $-1.02 | $-1.32 | -29.4% | $31M | +26.5% |
| May 5, 2022 | $-0.85 | $-1.20 | -41.2% | $24M | -2.4% |
| Feb 28, 2022 | $-0.78 | $-1.00 | -28.2% | $26M | +86.0% |
ARVN insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 26, 2026 | Bain Lindadirector | Grant | 22,714 | $8.05 |
| Jun 26, 2026 | Kennedy Edward Moore Jr.director | Grant | 22,714 | $8.05 |
| Jun 26, 2026 | Cunningham Everettdirector | Grant | 15,527 | — |
| Jun 26, 2026 | Norwalk Leslie Vdirector | Grant | 15,527 | — |
| Jun 26, 2026 | Smaldone Alsup Lauriedirector | Grant | 15,527 | — |
| Jun 26, 2026 | Norwalk Leslie Vdirector | Grant | 22,714 | $8.05 |
| Jun 26, 2026 | Smaldone Alsup Lauriedirector | Grant | 22,714 | $8.05 |
| Jun 26, 2026 | Bain Lindadirector | Grant | 15,527 | — |
| Jun 26, 2026 | Kennedy Edward Moore Jr.director | Grant | 15,527 | — |
| Jun 26, 2026 | Cunningham Everettdirector | Grant | 22,714 | $8.05 |
| Jun 26, 2026 | Morrison Briggsdirector | Grant | 22,714 | $8.05 |
| Jun 26, 2026 | Morrison Briggsdirector | Grant | 15,527 | — |
| Jun 24, 2026 | Saik Andrewofficer: Chief Financial Officer | Sell | 5,696 | $8.16 |
| Jun 18, 2026 | Cacace Angela Mofficer: Chief Scientific Officer | Sell | 2,576 | $7.59 |
| May 22, 2026 | Teel Randydirector, officer: President and CEO | Sell | 2,209 | $9.04 |
Source: ARVN SEC Form 4 filings, latest Jun 26, 2026. For informational purposes only — not investment advice.
See the full ARVN insider & 13F page →ARVN research & analysis
Arvinas, Inc. company profile
Overview
Arvinas, Inc. (NASDAQ:ARVN) is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in New Haven, Connecticut. The company pioneered the development of PROTAC (Proteolysis Targeting Chimera) protein degradation technology, a novel therapeutic approach that selectively degrades disease-causing proteins rather than simply inhibiting them. Since going public in 2018, Arvinas has advanced multiple drug candidates through clinical trials, with its lead breast cancer treatment vepdegestrant showing promising Phase 3 results in early 2025. The company has established strategic partnerships with major pharmaceutical companies including Pfizer, Genentech, Novartis, and Bayer to advance its innovative protein degradation platform.
Business
Arvinas operates in the biotechnology sector, specifically focusing on protein degradation therapeutics using its proprietary PROTAC technology platform. Unlike traditional small molecule drugs that typically inhibit protein function by blocking active sites, PROTAC molecules work by recruiting the cell's natural protein disposal system to selectively degrade target proteins entirely. This approach potentially offers advantages including the ability to target previously "undruggable" proteins, overcome drug resistance, and achieve more durable therapeutic effects. The company's pipeline spans two primary therapeutic areas. In oncology, Arvinas is developing treatments for various cancers including breast cancer, prostate cancer, and blood cancers. The lead oncology candidate is vepdegestrant, an estrogen receptor degrader being developed in partnership with Pfizer for metastatic breast cancer patients. Other oncology programs include ARV-393 targeting BCL6 protein in non-Hodgkin lymphoma and a KRAS degrader program for solid tumors. In neuroscience, the company is pioneering protein degradation approaches for neurodegenerative diseases. The lead neuroscience program is ARV-102, an LRRK2 protein degrader being developed for Parkinson's disease and Progressive Supranuclear Palsy. This represents a novel approach to treating neurological conditions by degrading proteins associated with disease pathology. The company generates revenue primarily through partnership agreements and milestone payments from pharmaceutical collaborators, with oncology programs representing the majority of current clinical development activities and revenue potential.
Revenue model
Arvinas generates revenue through multiple business models centered around its PROTAC technology platform. The primary revenue streams include upfront licensing fees, milestone payments, and research funding from pharmaceutical partnerships. For example, the company received significant payments from its collaboration with Novartis for ARV-766 (prostate cancer) and ongoing partnerships with Pfizer for vepdegestrant development. The company's paying customers are primarily large pharmaceutical companies seeking to leverage PROTAC technology for drug development. These partnerships typically involve cost-sharing arrangements where partners fund clinical development in exchange for commercialization rights in specific territories or indications. Arvinas retains co-commercialization rights in key markets, particularly the United States, which positions the company to capture both development milestone payments and future commercial revenue. Several factors influence Arvinas' financial performance and margins. Positive factors include the novelty and patent protection of PROTAC technology, which provides pricing power in partnership negotiations. The company's strong intellectual property position and first-mover advantage in protein degradation create opportunities for premium partnership terms. Successful clinical trial results, particularly positive Phase 3 data for vepdegestrant, significantly increase the value of partnership agreements and milestone payments. Negative factors include the high cost and risk associated with clinical-stage drug development, where failed trials can eliminate years of investment. The company faces intense competition from both traditional pharmaceutical approaches and emerging protein degradation competitors. Regulatory approval risks, manufacturing scale-up challenges, and the need for continued R&D investment to maintain technological leadership also pressure margins. Additionally, the company's current pre-commercial status means it relies heavily on partnership funding and faces significant cash burn until products reach market.
Competitive moat
Arvinas possesses a moderate to strong competitive moat built primarily on its pioneering position in PROTAC protein degradation technology and extensive intellectual property portfolio. The company was founded by the academic inventors of PROTAC technology and has accumulated substantial patents covering both the core platform and specific drug applications. This first-mover advantage has enabled Arvinas to establish partnerships with major pharmaceutical companies and advance the most clinically mature PROTAC programs. The company's moat is strengthened by the technical complexity and specialized expertise required to design effective PROTAC molecules. Unlike traditional small molecule drugs, PROTACs require sophisticated understanding of protein-protein interactions, cellular degradation pathways, and multi-target drug design. Arvinas has built proprietary computational platforms and accumulated years of experimental data that would be difficult for competitors to replicate quickly. However, the moat faces several potential threats. Large pharmaceutical companies are increasingly developing internal PROTAC capabilities and acquiring smaller competitors, potentially eroding Arvinas' partnership advantages. Academic institutions and biotechnology companies are advancing alternative protein degradation approaches, including molecular glues and other targeted protein degradation methods that could compete with or supersede PROTAC technology. Additionally, as foundational PROTAC patents expire over time, the barrier to entry for new competitors will decrease. The strength of Arvinas' moat ultimately depends on continued clinical success and the ability to demonstrate superior therapeutic outcomes compared to traditional approaches. The company's current Phase 3 results for vepdegestrant represent a critical test of whether PROTAC technology can deliver on its theoretical advantages in real-world clinical settings.
Risks & safety
Arvinas presents a moderate margin of safety for a clinical-stage biotechnology company, with strong liquidity but ongoing cash burn typical of pre-revenue biotech firms. Liquidity and Solvency: - Cash and short-term investments of $954 million as of Q1 2025, providing runway into second half of 2028 - Current ratio of 4.58, indicating strong short-term liquidity - Minimal debt with debt-to-equity ratio of only 0.016 - Quarterly cash burn reduced to approximately $89 million after workforce reduction and cost-cutting measures Valuation Metrics: - Trading at attractive valuation multiples: P/E ratio of 1.53 and P/B ratio of 0.77 following recent positive clinical results - EV/EBITDA of 1.51, though EBITDA was positive only due to partnership milestone payments - Graham number of $15.31 compared to current price, suggesting potential undervaluation Other Considerations: - Binary risk from Phase 3 clinical trial outcomes, particularly for lead asset vepdegestrant - Revenue concentration in partnership agreements creates dependence on pharmaceutical collaborators - Recent 33% workforce reduction demonstrates management's commitment to extending cash runway - Strong balance sheet provides flexibility to weather clinical setbacks or pursue strategic opportunities
Recent development
Over the past few years, Arvinas has undergone significant strategic evolution from a pure research-stage company to a clinical-stage organization preparing for potential commercialization. The most significant development was the positive Phase 3 VERITAC-2 results for vepdegestrant in ESR1 mutant breast cancer patients, announced in Q1 2025. This represents a potential breakthrough as the first PROTAC therapy to demonstrate Phase 3 efficacy. In response to capital market conditions and the need to focus resources, Arvinas implemented a major strategic restructuring in early 2025, reducing its workforce by approximately one-third and cutting annual operating costs by $80 million. This restructuring extended the company's cash runway into the second half of 2028 while maintaining focus on the highest-value programs. The company has strategically prioritized its pipeline around two core therapeutic areas: oncology and neuroscience. In oncology, beyond vepdegestrant's success, Arvinas discontinued certain combination trials with Pfizer while advancing new programs including a KRAS G12D degrader (ARV-806) that received IND filing clearance. The neuroscience program gained momentum with first-in-human data for ARV-102, the LRRK2 degrader, showing promising brain penetration and protein degradation in cerebrospinal fluid. Partnership strategy has evolved significantly, with Arvinas out-licensing ARV-766 to Novartis for prostate cancer development while maintaining co-development and co-commercialization rights for vepdegestrant with Pfizer. This approach balances risk-sharing with retention of commercial upside in key programs. The company has also begun preparing for its first potential commercial launch, establishing commercial leadership and planning a targeted go-to-market strategy focused on approximately 6,000 key oncologists.
ARVN company profile · for informational purposes only — not investment advice.
Track ARVN with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free